{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:02:53Z","timestamp":1777712573077,"version":"3.51.4"},"reference-count":81,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["The International Journal of Lower Extremity Wounds"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    Diabetic foot infections (DFIs) are a common and costly complication of diabetes. Soft tissue and bone infections in DFIs frequently lead to amputation and\/or sepsis which can be costly for both the patient and the healthcare system.\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    is the most commonly identified causative agent in DFIs, and people with diabetes may have an increased risk of infection with methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (MRSA). In addition to increased susceptibility to severe infection, MRSA in DFIs is associated with high rates of treatment failure, morbidity, and hospitalization costs meaning appropriate treatment is a high priority. While hospitalized patients are usually treated with intravenous (IV) vancomycin, this can be costly in terms of inpatient stays, staffing costs, and adverse events. For example, vancomycin-associated acute kidney injury not only delays hospital discharge and increases costs but is also a particular concern for patients with diabetes who already have an increased risk of kidney problems. Vancomycin-resistant strains of\n                    <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                    have also been identified, which means that alternative treatment options may need to be explored. Treatment alternatives to IV vancomycin, including oral antibiotics, have been shown to provide similar efficacy, with reduced costs, outpatient or home-based administration, and with fewer serious adverse effects. Although infectious disease specialists often use IV vancomycin alone, or in combination, as a first-line therapeutic option, they are increasingly seeing the value of outpatient or at-home oral antibiotics as an alternative. This manuscript reviews the evidence for true costs of vancomycin therapy for MRSA-associated DFIs and examines the alternatives.\n                  <\/jats:p>","DOI":"10.1177\/15347346231207553","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T04:33:16Z","timestamp":1698381196000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Parenteral Vancomycin in the Treatment of MRSA-Associated Diabetic Foot Infections: An Unnecessary Risk"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6750-579X","authenticated-orcid":false,"given":"Warren S.","family":"Joseph","sequence":"first","affiliation":[{"name":"Midwestern University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Kosinski","sequence":"additional","affiliation":[{"name":"New York College of Podiatric Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee C.","family":"Rogers","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center, San Antonio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2016.1231932"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1615439"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v8.i4.135"},{"issue":"1","key":"e_1_3_3_5_2","first-page":"71","article-title":"Diabetic foot infection","volume":"78","author":"Bader MS","year":"2008","unstructured":"Bader MS. Diabetic foot infection. Am Fam Physician. 2008;78(1):71\u201079.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365548.2013.765589"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac297"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06516-7"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01301-0"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-1893-7"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13047-020-00406-y"},{"key":"e_1_3_3_12_2","first-page":"52","article-title":"Bacterial profile of diabetic foot infections and antibiotic susceptibility in a specialized diabetes centre in Cameroon","volume":"42","author":"Yefou MD","year":"2022","unstructured":"Yefou MD, Jingi AM, Etoga MCE, et al. Bacterial profile of diabetic foot infections and antibiotic susceptibility in a specialized diabetes centre in Cameroon. Pan Afr Med J. 2022;42:52.","journal-title":"Pan Afr Med J"},{"issue":"1","key":"e_1_3_3_13_2","article-title":"Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update)","volume":"36","author":"Lipsky BA","year":"2020","unstructured":"Lipsky BA, Senneville \u00c9, Abbas ZG, et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020;36(Suppl 1):e3280.","journal-title":"Diabetes Metab Res Rev"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13205"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0161658"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08248-2"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534734619853668"},{"key":"e_1_3_3_18_2","unstructured":"US Food & Drug Administration. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. 2013. Cited March 2023. https:\/\/www.fda.gov\/media\/71052\/download"},{"key":"e_1_3_3_19_2","unstructured":"INVANZ (ertapenem) highlights of prescribing information. Accessed May 24 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021337s038lbl.pdf"},{"key":"e_1_3_3_20_2","unstructured":"ZYVOX (linezolid) highlights of prescribing information. Accessed May 24 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021130s032 021131s026 021132s031lbl.pdf"},{"key":"e_1_3_3_21_2","unstructured":"ZOSYN (piperacillin\/tazobactam) highlights of prescribing information. Accessed May 24 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050684s88s89s90_050750s37s38s39lbl.pdf"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3657"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2014.00217"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050606"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.11.002"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.36.7.3273"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/600877"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2019.10.005"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.027"},{"issue":"4","key":"e_1_3_3_30_2","first-page":"694","article-title":"The use of vancomycin with its therapeutic and adverse effects: a review","volume":"19","author":"Bruniera FR","year":"2015","unstructured":"Bruniera FR, Ferreira FM, Saviolli LR, et al. The use of vancomycin with its therapeutic and adverse effects: a review. Eur Rev Med Pharmacol Sci. 2015;19(4):694\u2010700.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0764-7"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05920616"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062784"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.08.001"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1259-9"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1442"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002769"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw709"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2683"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2020.08.004"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa303"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir034"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710926"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir842"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.130042"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i14.1825"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy867"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001825"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.4103\/0974-2727.119862"},{"issue":"7662","key":"e_1_3_3_51_2","article-title":"FDA Adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics","volume":"337","author":"Tanne JH","year":"2008","unstructured":"Tanne JH. FDA Adds \u201cblack box\u201d warning label to fluoroquinolone antibiotics. Br Med J. 2008;337(7662):a816.","journal-title":"Br Med J."},{"key":"e_1_3_3_52_2","unstructured":"US Food & Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. FDA Drug Safety Communication. Accessed May 09 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1086\/380449"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac055"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1086\/341026"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0352-7"},{"issue":"9","key":"e_1_3_3_57_2","first-page":"449","article-title":"Potential cost-savings with once-daily aminomethylcycline antibiotic versus vancomycin in hospitalized patients with acute bacterial skin and skin structure infections","volume":"11","author":"LaPensee K","year":"2018","unstructured":"LaPensee K, Lodise T. Potential cost-savings with once-daily aminomethylcycline antibiotic versus vancomycin in hospitalized patients with acute bacterial skin and skin structure infections. Am Health Drug Benefits. 2018;11(9):449\u2010459.","journal-title":"Am Health Drug Benefits"},{"issue":"4","key":"e_1_3_3_58_2","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden MS","year":"2011","unstructured":"Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(Suppl 4):iv7\u2010iv15.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171125"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0518-2"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01358-0"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx329"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01119-9"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30275-0"},{"key":"e_1_3_3_65_2","unstructured":"NUZYRA (omadacycline) prescribing information. Accessed March 21 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01099-7"},{"key":"e_1_3_3_67_2","unstructured":"Drugs.com FDA approves Sivextro. Accessed March 27 2023. https:\/\/www.drugs.com\/newdrugs\/fda-approves-sivextro-tedizolid-phosphate-skin-infections-4049.html"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-18"},{"issue":"6","key":"e_1_3_3_69_2","article-title":"Importance of nondrug costs of intravenous antibiotic therapy","volume":"7","author":"van Zanten ARH","year":"2003","unstructured":"van Zanten ARH, Engelfriet PM, van DK, van VM, Nuijten MJC, Polderman KH. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care. 2003;7(6):R184.","journal-title":"Crit Care."},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.15314.3"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049733"},{"key":"e_1_3_3_72_2","unstructured":"Institute for Clinical and Economic Review. Value assessment framework: final framework. 2020. Accessed March 20 2023. https:\/\/icer-review.org\/material\/2020-value-assessment-framework-final-framework\/"},{"key":"e_1_3_3_73_2","unstructured":"The National Institute for Health and Care Excellence. Consultation paper - value based assessment of health technologies. 2014. Accessed March 20 2023. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/NICE-guidance\/NICE-technology-appraisals\/VBA-TA-Methods-Guide-for-Consultation.pdf"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1177\/1558944719873145"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-018-0240-3"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-019-00278-1"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.4161\/viru.21657"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2021.204"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116207"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2021.252"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2022.302"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz386"}],"container-title":["The International Journal of Lower Extremity Wounds"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347346231207553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15347346231207553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15347346231207553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:05:48Z","timestamp":1777457148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15347346231207553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/15347346231207553"],"URL":"https:\/\/doi.org\/10.1177\/15347346231207553","relation":{},"ISSN":["1534-7346","1552-6941"],"issn-type":[{"value":"1534-7346","type":"print"},{"value":"1552-6941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}